Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S1W-11384 · Session 1

Further to the answer to question S1W-7241 by Susan Deacon on 1 August 2000 and the Scottish Needs Assessment programme report on multiple …

Answered Asked by Tricia Marwick SNP Lodged 20 Nov 2000

The question

To ask the Scottish Executive, further to the answer to question S1W-7241 by Susan Deacon on 1 August 2000 and the Scottish Needs Assessment programme report on multiple sclerosis (MS), whether it will assess the number of MS patients in each health board area who could benefit from prescription of Beta Interferon and what financial allocation will be made available for the prescription of the drug.

The answer

Answered by Susan Deacon on 4 Dec 2000 · 14 days after it was lodged, on time

Only certain patients with a diagnosis of multiple sclerosis are likely to benefit from the use of Beta Interferon. The question of whether an individual patient might benefit from this treatment is a matter for the clinical judgement of the specialist concerned, informed by advice and evidence about its use.Health boards receive a unified budget which includes provision for prescribing. These funds are intended to cover all pressures, including the provision of new drugs and the greater use of existing therapies.

In the Official Report

No contribution in the Official Report cites S1W-11384 by reference.